Vision: A domestic influenza vaccine enterprise that is highly responsive, flexible, scalable, and more effective at reducing the impact of seasonal and pandemic influenza viruses
The NIVMS provides a foundation on which the US Government (USG) and its partners can contribute to a common vision of a domestic influenza vaccine enterprise – one that is highly responsive, flexible, scalable, and more effective at reducing the impact of seasonal and pandemic influenza viruses.
The NIVMS seeks to inform governmental and non-governmental policies and programs; encourage coordinated planning and activities; and guide prioritization of investments of time, workforce, funds, and other resources.
To achieve this vision and carry out the four EO policy objectives, the NIVMS 2020-2030 is focused on three overarching strategic objectives:
- Strengthen and diversify influenza vaccine development, manufacturing, and supply chain;
- Promote innovative approaches and use of the new technologies to detect, prevent, and respond to influenza; and
- Increase influenza vaccine access and coverage across all populations.
All USG activities are subject to the availabilities of appropriations and standard budget development processes.
